Tagged with Access

USA So far in 2020 PharmaBoardroom has conducted interviews with several key stakeholders in US healthcare. We have heard from leaders the US FDA, as well as representatives of patient groups, health insurance providers, and firms operating in the US on what they consider the most pressing issues facing US healthcare.…

Belgium Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon goes on to explain GSK’s continued commitment to ensuring patients have access to innovative medicines, the role the company plays…

Belgium Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the increasing trend of personalized medicine, digitalization, big healthcare data, and stakeholder partnerships. Additionally, Van De Sompel also elaborates on Pfizer’s…

Belgium On 16 April 2020, a new Act was adopted by the Belgian parliament to increase the transparency of managed entry agreements (‘MEA’) concluded between pharmaceutical companies and the National Institute for Health and Disability Insurance (‘NIHDI’). MEAs stipulate confidential compensation mechanisms for the Belgian government regarding the publicly-listed price and reimbursement…

Morocco In 2020, PharmaBoardroom has met with stakeholders from across the Moroccan healthcare and life sciences industries. These interviewees range from general managers overseeing several countries in the region from a base in Morocco to association heads and key opinion leaders from the worlds of academia and policymaking. Several recurring themes…

Morocco Ali Besri, Pfizer Morocco GM and North Africa Lead reveals the importance of Morocco’s stability and assets allowing the country to be recognized internationally for its manufacturing investments and capabilities and highlights how Pfizer has capitalized on this with a footprint in the country for over half a century. Looking…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…

UAE Ousama Al Haj, director for UAE, Bahrain, Oman & Qatar at AstraZeneca, highlights the company’s substantial growth and favourable position in the Gulf markets, explains how the company is overcoming the local healthcare dynamics by partnering with local authorities to offer patients’ platforms instead of products, and analyzes AstraZeneca’s future…

Belgium Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate on the vast commitment Roche has to the Belgian market and the company’s mission not only to drive innovation but…

Morocco Alain Barry, managing director of MSD in Morocco, shares how the organization is partnering with the Moroccan healthcare community to ensure that patients have access to innovative therapies and vaccines.   Morocco has been a pioneer in the region in the field of immunization by introducing innovative vaccines in the…

Romania Sévan Kaloustian shares his first impressions of the Romanian healthcare ecosystem and pharmaceutical market as newly appointed managing director of Janssen Pharmaceutical Companies of Johnson & Johnson Romania. Kaloustian outlines his intention to maintain the strategic position of Janssen as a key player in Romania, working to facilitate the access…

Romania Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic producers, face in Romania: clawback tax, pricing methodology, and a low penetration rate of biosimilar medicines.   We are passing…